This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Hereditary transthyretin (ATTR) amyloidosis (familial amyloid polyneuropathy: FAP), which is a fatal disorder that is inherited in an autosomal dominant fashion, manifests features including accumulation of polymerized transthyretin (TTR) in systemic organs.1,2 Patients with ATTR V30M (p.TTR V50M) amyloidosis, who are found worldwide, mainly demonstrate polyneuropathy, whereas patients with non-V30M ATTR amyloidosis have various manifestations including heart failure (familial amyloid cardiopathy), renal impairment, cognitive impairment, and cerebral hemorrhage (leptomeningeal amyloidosis/cerebral amyloid angiopathy) in addition to polyneuropathy.2 The number of patients diagnosed with non-V30M ATTR amyloidosis has recently increased as a result of the utilization of genetic testing. However, the prognoses for the different phenotypes have not been well described.
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
Class of Evidence: NPub.org/coe
- Received November 1, 2018.
- Accepted in final form July 23, 2019.
- © 2019 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Alert Me
Recommended articles
Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy
Early skin denervation in hereditary and iatrogenic transthyretin amyloid neuropathy
Tafamidis for transthyretin familial amyloid polyneuropathy
Schwann cell and endothelial cell damage in transthyretin familial amyloid polyneuropathy